Ortho Clinical Diagnostics, a Carlyle-backed global provider of in vitro diagnostic products, announced terms for its IPO on Tuesday.
The company plans to raise $1.5 billion by offering 70 million shares at a price range of $20 to $23. At the midpoint of the proposed range, Ortho Clinical Diagnostics would command a fully diluted market value of $4.9 billion.
Acquired by The Carlyle Group in 2014, Ortho Clinical Diagnostics is a pure-play in vitro diagnostics (IVD) business that provides diagnostic testing solutions to the clinical laboratory and transfusion medicine communities, impacting approximately 800,000 patients every day.
Ortho Clinical Diagnostics was founded in 1939 and booked $1.7 billion in revenue for the 12 months ended September 30, 2020 and it plans to list on the Nasdaq. J.P. Morgan, BofA Securities, Goldman Sachs, Barclays, Morgan Stanley, Citi, Credit Suisse, UBS Investment Bank, Evercore ISI and Piper Sandler are the joint bookrunners on the deal. It is expected to price during the week of January 25, 2021.
Source: Reuters
Can’t stop reading? Read more
Exclusive Interview: Andrei Gemeneanu on building Romania’s private equity future
Exclusive Interview: Andrei Gemeneanu on building Romania's private equity future Andrei...
Shore Capital’s Justin Ishbia agrees $1.8bn path to control of MLB’s Chicago White Sox
Shore Capital’s Justin Ishbia agrees $1.8bn path to control of MLB’s Chicago White Sox Justin...
EQT to acquire controlling stake in Waga Energy in €534m clean energy push
EQT to acquire controlling stake in Waga Energy in €534m clean energy push EQT is set to acquire a...